Evaluating Patient Preferences for the Treatment of EGFR-Mutant mNSCLC

EP: 1.The Evolution of EGFR-Mutated Advanced NSCLC Treatment: Present Considerations and Future Treatment Options

EP: 2.Has Combination Therapy Become the New Frontline Treatment Standard for EGFR-Mutant Metastatic NSCLC?

EP: 3.Decision Points to Consider When Choosing Treatment With Monotherapy or Combination Therapy for EGFR-Mutant mNSCLC

Now Viewing

EP: 4.Evaluating Patient Preferences for the Treatment of EGFR-Mutant mNSCLC

EP: 5.Comparing the Combination Therapies for the Treatment of EGFR-Mutant mNSCLC

EP: 6.Considering Resistance Mechanisms When Choosing Therapy in the Frontline Setting

EP: 7.The Importance of Maintaining Quality of Life and Intervening Early When Adverse Events Occur in the Frontline Treatment Setting

EP: 8.Weighing the 1-Year Projected Overall Survival Benefit With MARIPOSA in the Frontline Treatment of EGFR-Mutant mNSCLC

EP: 9.Discussing the Time and Financial Toxicities Associated With Combination Therapies and Potential Mitigation Strategies

EP: 10.Discussing Potential Combination Therapy Medication-Associated Toxicities With Patients

EP: 11.Evaluating the Clinical Utility of Subcutaneous Amivantamab in the Treatment of EGFR-Mutant mNSCLC

EP: 12.The Importance of Multidisciplinary Collaboration With Subspecialty Physicians in the Toxicity Management With Treatment

EP: 13.Exploring Second-Line Treatment Options Including Targeted Radiation and Surgery for the Management of EGFR-Mutant mNSCLC

EP: 14.Tissue vs Plasma Biopsy After First Disease Progression in EGFR-Mutant NSCLC

EP: 15.Deciding Between a Biomarker-Directed Approach and a Biomarker-Agnostic Approach for Second-Line Treatment of EGFR-Mutant NSCLC

EP: 16.Continuing the Targeted TKI in the Second Line for the Treatment of EGFR-Mutant NSCLC

EP: 17.When to Consider Retreatment With Chemotherapy After FLAURA2 for EGFR-Mutant NSCLC

EP: 18.Patient Case Presentation: A 45-Year-Old With Newly Diagnosed EGFR-Mutant mNSCLC and Liver Metastases

EP: 19.Patient Case Presentation: A 69-Year-Old With Newly Diagnosed EGFR-Mutant mNSCLC and Symptomatic Brain Metastases

This segment addresses the diverse range of patient knowledge and preferences encountered when treating EGFR-mutant metastatic non–small cell lung cancer (mNSCLC). The panel discusses how patient preparation varies significantly, from those arriving with minimal medical knowledge to highly informed individuals who have extensively researched their condition. A small percentage of patients come with specific treatment regimens in mind, though these may not always be applicable to their particular disease state. The majority of patients rely on their oncology team’s clinical experience to explore all applicable treatment options, emphasizing the importance of shared decision-making in formulating treatment plans that align with individual goals of care.

Patient demographics and educational backgrounds significantly influence their approach to treatment discussions. The panel notes that EGFR-mutant lung cancer often affects patients with high educational attainment, such as engineers, who frequently conduct extensive research using internet resources and AI tools like ChatGPT. These patients often arrive having done considerable homework and may subtly test whether physician recommendations align with their independent research. Medical literacy varies dramatically across the patient population, with some having limited understanding of their medical history while others benefit from health care professionals within their families who can help interpret complex information.

The clinical approach emphasizes meeting patients where they are in their understanding and decision-making process. Physicians focus on understanding the reasoning behind patient preferences, as this insight reveals their thought processes and concerns. For instance, when patients express fear of chemotherapy, exploring the source of that fear through previous experiences or misconceptions can help determine whether combination therapy with chemotherapy might still be appropriate. The panel acknowledges that having multiple treatment options is beneficial for patients, but this abundance of choices requires careful guidance to ensure patients receive comprehensive information needed for informed decision-making. Second opinion consultations are common, allowing patients to compare different physician perspectives before finalizing treatment plans.